ARGOS THERAPEUTICS INC (ARGS) financial statements (2020 and earlier)

Company profile

Business Address 4233 TECHNOLOGY DR
DURHAM, NC 27704
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:1553756
Cash and cash equivalents1553637
Short-term investments  119
Other undisclosed cash, cash equivalents, and short-term investments 00 
Restricted cash and investments  1 
Receivables0000
Deferred costs  00
Assets held-for-sale, not part of disposal group11 
Other undisclosed current assets1111
Total current assets:1756958
Noncurrent Assets
Property, plant and equipment441226
Restricted cash and investments 1 1
Other noncurrent assets0000
Total noncurrent assets:442227
TOTAL ASSETS:21973164
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities21573
Accounts payable1532
Accrued liabilities11041
Debt51120
Other undisclosed current liabilities24  
Total current liabilities:103183
Noncurrent Liabilities
Long-term debt and lease obligation12193823
Long-term debt, excluding current maturities12193120
Capital lease obligations  73
Liabilities, other than long-term debt621  
Due to related parties6   
Derivative instruments and hedges, liabilities021  
Other undisclosed noncurrent liabilities 21 7
Total noncurrent liabilities:19603830
Total liabilities:28914633
Stockholders' equity
Stockholders' equity attributable to parent(9)6(28)31
Common stock0000
Additional paid in capital363338251236
Accumulated other comprehensive loss(0)(0)(0)(0)
Accumulated deficit(373)(332)(279)(204)
Total stockholders' equity:(9)6(28)31
Other undisclosed liabilities and equity2 13 
TOTAL LIABILITIES AND EQUITY:21973164

Income statement (P&L) ($ in millions)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:2112
Operating expenses(64)(53)(73)(54)
Operating loss:(62)(52)(73)(52)
Nonoperating income (expense)22(1)(2)(1)
Other nonoperating income (expense)0(0)(0)(0)
Interest and debt expense2(2)(2)(1)
Loss before gain (loss) on sale of properties:(38)(55)(77)(54)
Other undisclosed net income   1
Net loss:(38)(55)(77)(53)
Other undisclosed net income (loss) attributable to parent(2)22 
Net loss attributable to parent:(41)(53)(75)(53)
Other undisclosed net loss available to common stockholders, basic   (1)
Net loss available to common stockholders, diluted:(41)(53)(75)(54)

Comprehensive Income ($ in millions)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(38)(55)(77)(53)
Other undisclosed comprehensive income (loss)(2)22(0)
Comprehensive loss, net of tax, attributable to parent:(41)(53)(75)(53)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: